The loss of peripheral sensations, affecting diabetic peripheral neuropathy (DPN)(237 M patients), is a severe risk factor for altered gait biomechanics, balance impairment, increased falls risk and chronic pain development.
MYNERVA produced a peerless revolutionary non-invasive device to tackle all these symptoms, Leia: a groundbreaking device that offers a reprieve from the vicious cycle of pain and sensory loss. It is a wearable neurostimulating device able to restore the sense of touch and alleviate pain through pleasant, non-invasive AI-driven electrical stimulation, all within the familiar form factor of a sock.
24.06.2025
The >>venture>> Grand Prize goes to MYNERVA (startupticker.ch)
22.11.2024
Venture Leaders Medtech 2024: Captain's blog by Shelley Horn, Business Developer of MYNERVA (venturelab.swiss)
12.11.2024
Venture Leaders Medtech roadshow 2024: A report from Boston (venturelab.swiss)
01.11.2023
prototype
20.10.2022
IP
21.05.2022
clinical validation
No Jobs
No videos and documents
No Awards
Website:
www.mynervamedical.com
Headquarter:
zurich
Foundation Date:
June 2025
Technology:
Sectors: